Idiopathic Recurrent Acute Pancreatitis (IRAP)

The IRAP Registry is a Multi-center Prospective, Collaborative Database Designed to Create a National Registry That Collects Information Concerning Episodes of Idiopathic Recurrent Acute Pancreatitis From Major 'Pancreas' Centers. Intent is to do a Comparative Effectiveness Study of Interventions.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01133535

Acronym

IRAP

Enrollment

Registered

2010-05-31

Start date

2010-06-30

Completion date

2014-04-30

Last updated

2024-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatitis

Brief summary

The purpose of this study is to collect standardized data on the diagnosis and management of idiopathic (unknown cause) recurrent acute pancreatitis. The intent is to collect data for at least five years to obtain information regarding long-term outcomes and obtain comparative effectiveness data.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. 18 years or older 2. Able to provide consent 3. More than one documented episode of pancreatitis (\>3 fold elevation of amylase and or lipase with abdominal pain or with body imaging consistent with pancreatitis: need two of the three) 4. Subjects with abdominal pain and enzyme elevation which is \<3 fold above normal or absence of imaging findings: these subjects who are undergoing endoscopic interventions but do not fit the classic criteria for pancreatitis will be included but the analysis of data of these subjects would be done separately. Note: subjects with a diagnosis of pancreas divisum and or Sphincter of Oddi dysfunction diagnosed prior to or after entry into the study will be included in the study but their data will be analyzed separately because of the controversy regarding the association of these entities with pancreatitis.

Exclusion criteria

1. Unable to give informed consent. 2. Definite evidence of biliary or alcoholic pancreatitis. 3. Clear evidence of hypertriglyceridemia-induced pancreatitis (triglycerides \>1,000 mg/dl). 4. Post-ERCP pancreatitis, drug-induced pancreatitis, or any identifiable cause for pancreatitis. 5. History of pancreatic surgery.

Design outcomes

Primary

Measure	Time frame	Description
IDIOPATHIC RECURRENT ACUTE PANCREATITIS (IRAP)	The goal is to recruit 1000 subjects in 5 years.	Expect 750 to be treated with ERCP Expect 250 to be treated with conservative treatment. Therefore, the smaller group was used for the sample size analysis. Smallest difference in QOL for treatment is expected to be 10-20%. For smaller of two treatment groups (N=250), no effect would be 0 got better and 250 did not. If 10% of the subjects improved, 25 would get better and 225 would not. Result: Chi-square analysis yielded a highly significantly difference as follows. Chi-square= 24.253 with 1 degrees of freedom. (P = \<0.001). Yates correction for continuity was used in calculating this test.An alternate analysis is that for no effect, 125 subjects would get better and 125 patients would not (random effects model).

Countries

United States

Outcome results